Saroglitazar

-Saroglitazar is a medication belonging to the class of peroxisome proliferator-activated receptor (PPAR) agonists. It is primarily used for the treatment of dyslipidemia and hypertriglyceridemia, commonly associated with diabetes mellitus. -Saroglitazar is a dual regulator that corrects both the lipid profile and the glycemic indices. It is a potent and predominantly Peroxisome Proliferator Activated Receptor (PPAR)-alpha agonist with moderate PPAR-gamma agonistic activity. PPARs are nuclear lipid-activated transcription factors that regulate the expression of various genes involved in the control of lipid and lipoprotein metabolism, glucose homeostasis and inflammatory processes. It decreases the post prandial rise of plasma free fatty acids, improves post-absorptive insulin-mediated suppression of hepatic glucose output, reduces the metabolic burden on liver & muscle and promotes glucose utilization.

Indications

-Saroglitazar is indicated for the management of dyslipidemia, specifically in patients with type 2 diabetes mellitus, to reduce elevated triglyceride levels and increase high-density lipoprotein (HDL) cholesterol. -For diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by statin therapy. It has also shown favorable glycemic indices by reducing the fasting plasma glucose and glycosylated hemoglobin in diabetic patients.

Dosage

-The dosage of Saroglitazar should be determined by a healthcare professional based on individual patient characteristics. Typically, the recommended dose is once daily, with or without food. It is important to adhere to the prescribed dosage for optimal therapeutic effects. -Oral; 4mg once a day.

Contra-Indications

-Saroglitazar is contraindicated in individuals with known hypersensitivity to the drug or its components. It should not be used in patients with active liver disease or severe renal impairment. Pregnant and lactating women are advised to avoid its use. -Hypersensitivity to saroglitazar.

Special Precautions

-Saroglitazar is contraindicated in individuals with known hypersensitivity to the drug or its components. It should not be used in patients with active liver disease or severe renal impairment. Pregnant and lactating women are advised to avoid its use. Paediatric: Safety and efficacy of saroglitazar in pediatric patients have not been established. Pregnancy: Category C; It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: it is not known whether Saroglitazar is excreted into the breast milk. Elderly: It should be used with caution in geriatric patients.

Side Effects

-Special precautions should be taken in patients with a history of liver disorders or abnormalities. Regular monitoring of liver function tests is recommended during treatment. Caution is advised in elderly patients, and the potential benefits should be weighed against the risks. -Gastritis, asthenia and pyrexia.

Drug Interactions

Saroglitazar may interact with certain medications, including oral anticoagulants, leading to an increased risk of bleeding. Concurrent use with CYP2C8 inhibitors or inducers should be carefully monitored. Patients should inform their healthcare providers about all medications, including over-the-counter drugs and herbal supplements.